The effect of retinal autoantigens and their peptides on the inhibition of experimental autoimmune uveitis

Dua, Harminder S.; Abrams, Michael S.; Barrett, Jeffrey; Donoso, Larry A.

doi:10.1038/eye.1992.94

Cited by 5 publications

(1 citation statement)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…S-antigen or interphotoreceptor retinoid binding protein) are protected from experimental autoimmune uveitis [46,47]. Suppression of immunological responsiveness by single or multiple doses of autoantigens via oral, intranasal and intravenous routes has been demonstrated to suppress uveitis in rodent models [48][49][50][51].…”

Section: Tolerance Induction For the Treatment Of Anterior Uveitismentioning

confidence: 99%

Intraocular Diseases – Anterior Uveitis

Bora

Kaplan²

2007

Chemical Immunology and Allergy

View full text Add to dashboard Cite

Uveitis is a general term for inflammatory disorders of the uveal tract and encompasses a wide range of underlying etiologies. It may be idiopathic, associated with systemic diseases or result from a variety of infectious agents. Uveitis is responsible for over 2.8% of blindness in the United States. Each year, 17.6% of active uveitis patients experience a transient or permanent loss of vision. Anterior uveitis (AU), which refers to inflammation within the anterior segment of the eye, is the most common form of uveitis. Experimental autoimmune AU (EAAU) is an organ-specific autoimmune disease of the eye, which serves as an animal model of idiopathic human AU. Recently, type I collagen was identified as the target autoantigen in EAAU. Thus, human AU may be an e xample of autoimmunity to local ocular collagen.

show abstract

Section: Tolerance Induction For the Treatment Of Anterior Uveitismentioning

confidence: 99%

Intraocular Diseases – Anterior Uveitis

Bora

Kaplan²

2007

Chemical Immunology and Allergy

View full text Add to dashboard Cite

show abstract

Experimental Autoimmune Disease Models

Tizard¹

2023

Autoimmune Diseases in Domestic Animals

View full text Add to dashboard Cite

Antigenic Specificity of Immunoprotective Therapeutic Vaccination for Glaucoma

Bakalash

Kessler

Mizrahi

et al. 2003

Invest. Ophthalmol. Vis. Sci.

View full text Add to dashboard Cite

To benefit damaged neurons, immune neuroprotection should be directed against immunodominant antigens that reside in the site of damage. In a rat model of high IOP, RGCs can benefit from vaccination with peptides derived from proteins that are immunodominant in the eye but not from myelin-associated proteins. This suggests that the site of primary degeneration in IOP-induced RGC loss is in the eye. Cop-1 vaccination apparently circumvents the site-specificity barrier and provides protection without risk of inducing autoimmune disease.

show abstract

The effect of retinal autoantigens and their peptides on the inhibition of experimental autoimmune uveitis

Abstract: SUMMARYExperimental autoimmune uveitis is an immune mediated inflammation of the retina and uveal tract.

Cited by 5 publications

References 26 publications

Intraocular Diseases – Anterior Uveitis

Intraocular Diseases – Anterior Uveitis

Experimental Autoimmune Disease Models

Antigenic Specificity of Immunoprotective Therapeutic Vaccination for Glaucoma

Contact Info

Product

Resources

About